Yes, it’s possible
to sweat less.
Your cure for excessive underarm sweat with no out of pocket expenses.
- Treatable in less than 5 minutes.
- Finally be free of underarm sweat.
- Bulk-billed with referral from your GP
- There is a separate pharmacy prescription fee.
Do you sweat a lot,
even when you’re not doing much?
Axillary Hyperhidrosis is a medical condition that affects about 3% us Australians. But instead of ‘putting up with it’, for the first time there’s a 100% bulk-billed treatment.
And it takes less 5 minutes to treat.Find out if this treatment is for you
Excessively sweaty armpits are also referred to as Axillary Hyperhidrosis, and it’s a medical condition that affects approximately 3% of the population. Sufferers of Axillary Hyperhidrosis often report the illness impacts the clothes they wear, attending social events, and negative effects on their self-confidence.
A referral will allow you to be entirely bulk billed for the consultation and procedure. This referral is valid for 12 month if you require further treatments in that time. No referral is necessary to visit No Sweat Doc. However without a referral, you are required to pay a fee of $230.70 which is entirely reimbursed by Medicare.
It’s important that everyone who needs this treatment can afford it. For that reason, No Sweat Doc will bulk-bill your treatment with a referral from your GP. Without a referral, you are required to pay a fee of $230.70 at the appointment which is entirely reimbursed by Medicare.
The only out of pocket cost is the PBS pharmacy prescription fee for the botulinum toxin. A PBS nominated pharmacy mails you an invoice for $38.80 or $6.30 if you are a healthcare card, pension concession card , commonwealth seniors health card, DVA card or safety net concession card holder. You then pay the pharmacy directly for the prescription.
All treatments are administered by a highly qualified specialist Dermatologist. You’ll be in the best possible care by our experienced skin specialists.
You can visit a No Sweat Doc once every 4 months, and Medicare will subsidises this procedure. Most patients have at least 4 months of therapeutic benefit from the treatment. It can last up to 9 months, or occasionally 2-3 months. This means the majority of people need never worry about excessive sweating again.
In summary, a patent qualifies for the Medicare subsidy if they have significant armpit sweating not responsive to Drichlor.
Medicare states the patient is eligible for coverage if:
(a) the patient is at least 12 years of age; and
(b) the patient has been intolerant of, or has not responded to, topical aluminium chloride hexahydrate; and
(c) the patient has not had treatment with botulinum toxin within the immediately preceding 4 months; and
(d) if the patient has had treatment with botulinum toxin within the previous 12 months – the patient had treatment on no more than 2 separate occasions
The treatment may be uncomfortable or sting. Rare patients have compensatory hyperhidrosis meaning that there is an excess of sweating elsewhere beyond the armpits.
This treatment should not be provided to patients who have an allergy to botulinum toxin, have an infection/inflammation in the armpits, are pregnant, or suffer from known neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome. The injections should not be performed in patients taking aminoglycoside antibiotics, calcium channel blockers, cholinesterase inhibitors or quinidine. Injections should not be provided to patients with unrealistic expectations or psychiatric illnesses such as body dysmorphic disorder.
COMPLIANCE WITH ADVERTISING GUIDELINES
This advertisement complies with the AHPRA Guidelines for advertising regulated health services. In summary, information provided about this treatment is true and without inducement. No testimonials are used. This advertisement creates realistic expectations of benefit from the treatment. This advertisement is to help people who suffer from axillary hyperhidrosis recognise that they have a medical condition and are eligible for Medicare funded treatments. Hence we support the use of this treatment in appropriate patients suffering from axillary hyperhidrosis unresponsive to first line treatments such as topical Drichlor or Rexona Clinical Protection underarm antiperspirant.